+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 14Years +
All Genders
Healthy Volunteers
ID07912983

Metabolomic Biomarkers Study for Myotonic Dystrophy Using Urine and Blood Samples

Led by Massachusetts General Hospital · Updated on 2026-11-03

64

Participants Needed

1

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying myotonic dystrophy type 1 to find less invasive ways to measure disease activity and severity. Current methods often require muscle biopsies, which can be uncomfortable and invasive. This research aims to explore whether urine and blood samples, along with muscle function tests, can provide useful information about this condition. The study is observational and seeks to improve understanding, diagnosis, and treatment approaches for myotonic dystrophy. Participants will provide urine and blood samples and undergo muscle function testing. These samples and tests will be used to analyze metabolomic biomarkers that could reflect the diseases activity without needing muscle tissue biopsies. The study includes both individuals diagnosed with myotonic dystrophy and unaffected participants to compare findings over time. Throughout the study, participants will be monitored and assessed at regular intervals for up to five years. Researchers will measure extracellular vesicle metabolite profiles as the primary outcome to evaluate disease markers. Participants involvement includes providing samples and undergoing muscle tests, with ongoing data collection to enhance knowledge about myotonic dystrophy and support future improvements in care and treatment.

CONDITIONS

Brief Title

Metabolomic Biomarkers of Myotonic Dystrophy

Research Team

T

Tamkin Shahraki, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here